Northwest Biotherapeutics Gets Cash Infusion

The Richard M. Schulze Foundation made an equity investment in Bethesda based Northwest Biotherapeutics, Inc.

The microcap biotech received $4.55 million from the foundation on June 28th, 2011.

Currently in Phase III of its leading drug DCVax -Prostate, as the name implies, the treatment was developed as a new way to battle prostate cancer.

 Northwest focuses on creating treatments using personalized medicine techniques, the company moved to Montgomery County, Maryland from the Seattle, Washington area in 2007.


Stocks, Trading and Investing